The Possibility of the Serum Concentration of Osteocalcin Determination in Lung Cancer Patients with Suspected Bone Metastases
Authors:
J. Weissensteiner 1; E. Babušíková 2
Authors‘ workplace:
Oddelenie nukleárnej medicíny, Nemocnica Poprad, a. s., Slovenská republika
1; Ústav lekárskej bio chémie, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Martin, Slovenská republika
2
Published in:
Klin Onkol 2015; 28(1): 51-56
Category:
Original Articles
doi:
https://doi.org/10.14735/amko201551
Overview
Aim:
The aim of this study was to compare serum levels of biochemical markers of bone metabolism – osteocalcin (OC) in correlation with bone metastases found during whole-body bone scintigraphy in patients with lung cancer.
Material and Methods:
The serum levels of OC as a bone formation marker were determined in 60 patients (46 male, 14 female, mean age 66.65, range 50–84 years) with lung cancer (51 non-small-cell lung cancers – NSCLC and nine small-cell lung cancers – SCLC) and correlated with the presence of bone metastases detected by whole-body bone scintigraphy (hybrid system SPECT/CT: BrightView XCT, Philips Healthcare). Whole-body bone scintigraphy results were compared with OC for each patient with lung cancer and for person from control group of 10 persons (two males, eight females, mean age 52.3, range 34–67 years) without malignant disease.
Results:
By whole-body bone scintigraphy, bone metastases were found in 15 cases (25%), probably in 11 cases (18.33%) and 34 patients (56.67%) were without bone metastases out of 60 patients with lung cancer. The serum levels of OC were above reference range in five cases (8.33%) only with NSCLC and below reference range in 12 cases (20%) – in 10 cases in patients with NSCLC and in two cases in patients with SCLC. In control group of 10 persons, serum level of OC was below reference range only in one case.
Conclusion:
The serum concentrations of osteocalcin were not correlated with findings performed bywhole-body bone scintigraphy in patients with lung cancer. Osteocalcin serum levels determination probably does not have diagnostic importance in lung cancer patients with suspected bone metastases.
Key words:
cancer – lung – scintigraphy – metastasis – bone – osteocalcin
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
12. 10. 2014
Accepted:
17. 11. 2014
Sources
1. Vansteenkiste J, De Ruysscher D, Eberhardt WE et al. Early and locally advanced non‑small‑cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2013; 24 (Suppl 6): 89– 98. doi: 10.1093/ annonc/ mdt241.
2. D’Addario G, Felip E. Non‑ small‑cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow‑up. Ann Oncol 2009; 20 (Suppl 4): 68– 70. doi: 10.1093/ annonc/ mdp132.
3. Singh CR, Kathiresan K. Molecular understanding of lung cancers‑ A review. Asian Pac J Trop Biomed 2014; 4 (Suppl 1): 35– 41. doi: 10.12980/ APJTB.4.2014C597.
4. Sørensen M, Felip E. Small‑cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow‑up. Ann Oncol 2009; 20 (Suppl 4): 71– 72. doi: 10.1093/ annonc/ mdp133.
5. Früh M, De Ruysscher D, Popat S et al. Small‑cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2013; 24 (Suppl 6): 99– 105. doi: 10.1093/ annonc/mdt178.
6. Peters S, Adjei AA, Gridelli C et al. Metastatic non‑small‑cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2012; 23 (Suppl 7): 56– 64.
7. Gupta S, Hassan S, Bhatt VR et al. Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University’s lung cancer patients. Int J Gen Med 2014; 2(7): 333– 337. doi: 10.2147/ IJGM.S55806.
8. Florou AN, Gkiozos IC, Tsagouli SK et al. Clinical significance of smoking cessation in patients with cancer: a 30‑year review. Respir Care 2014; 59(12): 1924– 1936.
9. Choi H, Mazzone P. Radon and lung cancer: assessing and mitigating the risk. Cleve Clin J Med 2014; 81(9): 567– 575. doi: 10.3949/ ccjm.81a.14046.
10. Dawe DE, Greenspoon JN, Ellis PM. Brain metastases in non‑small‑cell lung cancer. Clin Lung Cancer 2014; 15(4): 249– 257. doi: 10.1016/ j.cllc.2014.04.008.
11. Lukas RV, Lesniak MS, Salgia R. Brain metastases in non‑small‑cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol 2014; 3(1): 61– 75. doi: 10.2217/ cns.13.66.
12. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Res 2006; 12(20): 6243– 6249.
13. Sugiura H, Yamada K, Sugiura T et al. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008; 466(3): 729– 736. doi: 10.1007/ s11999‑ 007‑ 0051‑ 0.
14. Jung RS, Mittal BR, Santhosh S et al. Is femoral uptake of Tc99m‑ methylene diphosphonate on bone scintigraphy in bronchogenic carcinoma an alarming sign: a case report and brief review of literature? Lung India 2014; 31(3): 280– 281. doi: 10.4103/ 0970‑ 2113.135779.
15. Aruga A, Koizumi M, Hotta R et al. Usefulness of bone metabolic markers in the diagnosis and follow‑up of bone metastasis from lung cancer. Br J Cancer 1997; 75(6): 760– 764.
16. Kane T, Kulshrestha R, Notghi A et al. Clinical Utility (Applications) of SPECT/ CT. In: Jones DW, Hogg P, Seeram E et al (eds). Practical SPECT/ CT in Nuclear Medicine. London: Springer‑ Verlag 2013: 345.
17. Kuwert T. Bone Imaging with SPECT‑ CT. In: Fanti S, Farsad M, Mansi L et al (eds). Atlas of SPECT/ CT. Berlin: Springer – Verlag Heidelberg 2011: 229.
18. Makaiová I. Scintigrafie skeletu. In: Kupka K, Kubinyi J, Šámal M et al (eds). Nukleární medicína. 1. vyd. Příbram: P3K 2007: 116– 124.
19. Kardamakis D, Vassilious V, Chow E. Bone metastases. A Translational and Clinical Approach. Springer Science + Business Media B.V. 2009: 400.
20. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000; 37(4): 432– 446.
21. Hamidi MS, Gajic‑ Veljanoski O, Cheung AM. Vitamin K and bone health. J Clin Densitom 2013; 16(4): 409– 413. doi: 10.1016/ j.jocd.2013.08.017.
22. Okano T. Gla‑ containing proteins. Clin Calcium 2014; 24(2): 241– 248. doi: CliCa1402241248.
23. Bae HM, Lee SH, Kim TM et al. Prognostic factors for non‑small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 2012; 77(3): 572– 577. doi: 10.1016/ j.lungcan.2012.05.094.
24. Niu YJ, Wen YT, Shen WW et al. Risk factors for bone metastasis in patients with primary lung cancer: study protocol for systematic review. BMJ Open 2014; 4(7): e005202. doi: 10.1136/ bmjopen‑ 2014‑ 005202.
25. Bilgin E, Yasasever V, Soydinc HO et al. Markers of bone metastases in breast and lung cancers. Asian Pac J Cancer Prev 2012; 13(9): 4331– 4334.
26. Valencia K, Martin‑Fernández M, Zandueta C et al. miR‑ 326 associates with biochemical of bone tunover in lung cancer bone metastasis. Bone 2013; 52(1): 532– 539. doi: 10.1016/ j.bone.2012.10.033.
27. Bayrak SB, Ceylan E, Serter M et al. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 2012; 17(2): 112– 118. doi: 10.1007/ s10147‑ 011‑ 0266‑ 7.
28. Terpos E, Kiagia M, Karapanagiotou EM et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 2009; 29(5): 1651– 1657.
29. Karapanagiotou EM, Terpos E, Dilana KD et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 2010; 27(2): 332– 338. doi: 10.1007/ s12032‑ 009‑ 9214‑ z.
30. Dane F, Turk HM, Sevinc A et al. Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 2008; 100(4): 425– 428.
31. Kong QQ, TuCQ, Dou QY et al. Bone turnover markers in the detection of bone metastases in primary lung cancer. Sichuan Da Xue Bao Yi Xue Ban 2005; 36(3): 397– 399.
32. Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res 2004; 22(6): 1161– 1167.
33. Alatas F, Alatas O, Metintas M et al. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 2002; 35(4): 293– 296.
34. Aruga A, Koizumi M, Hotta R et al. Usefulness of bone metabolic markers in the diagnosis and follow‑up of bone metastasis from lung cancer. Br J Cancer 1997; 76(6): 760– 764.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2015 Issue 1
Most read in this issue
- Sarcomatoid Carcinoma of the Lung – a Case Report
- Assessment of the Spiritual Needs of Patients in Palliative Care
- Management of Patients with Castration‑resistant Metastatic Prostate Cancer
- The Possibility of the Serum Concentration of Osteocalcin Determination in Lung Cancer Patients with Suspected Bone Metastases